Perrigo Company and Paddock Laboratories, Inc., In the Matter of

Last Updated:
In the Matter of Perrigo Company and Paddock Laboratories, Inc.
FTC Matter/File Number:

111 0083

Docket Number:

C-4329

Enforcement Type:

Part 2 Consents

Case Summary

On 7/26/2011, the Commission required generic drug manufacturers Perrigo Company and Paddock Laboratories, Inc. to sell six generic drugs under a proposed settlement resolving charges that Perrigo’s proposed $540 million acquisition of Paddock would be anticompetitive. The proposed settlement also contains provisions to ensure future competition in the market for generic testosterone gel product. On 6/26/2012, the FTC issued a modified final order that required the companies to sell six generic drugs to Watson Pharmaceuticals, Inc.